Oxford Vaccine ‘Covishield’ trials to be resumed in India

News Posted on

Pharmaceutical company AstraZeneca gets permission to try with British regulator.

New Delhi, 12 September: Trial of Oxford Vaccine Covishield can be resumed in India.

Human trials of the corona vaccine have been resumed after drug company AstraZeneca received a green signal from the British regulator.

During the trial of the vaccine, a volunteer had to stop midway due to falling ill. After this, the trial of this vaccine was also halted in India.

On Saturday, the company said in a statement, “The clinical trial of the AstraZeneca Oxford Corona Virus Vaccine has been resumed in the UK once again.” Medicine Health Regulatory Authority has confirmed its safety. ”

AstraZeneca prohibited further trials when a volunteer involved in a human trial fell ill during his final phase trial in Britain.

However, it has not adversely affected any volunteer in the Oxford vaccine trial in India.

In the second phase trial, more than 100 volunteers were given the vaccine, but even after a week’s completion, they have not seen any wrong reaction.

 A day after receiving a show cause notice from the Drugs Controller General of India (DCGI), the Indian pharmaceutical manufacturer Serum Institute of India said that it is stopping the trials of Covid-19 vaccine in the country.

The Serum Institute is preparing the Covishield vaccine of Oxford University in India along with AstraZeneca of Britain.

Controller General VG Somani, in an order on Friday, also asked the Serum Institute of India (SII) to increase the safety monitoring of those who had been vaccinated during the trial. Also present plans and reports.

As per the order, Somani has also asked the company to submit the approval from the Data and Safety Monitoring Board (DSMB) in the UK and India for prior approval from their office (DCGA) before making new recruits for future tests.

How useful was this News?

Click on a star to rate it!

Average rating 5 / 5. Vote count: 1

No votes so far! Be the first to rate this news.

As you found this news useful...

Follow us on social media!